Standigm, Inc. and CrystalGenomics, Inc. today agree collaborative partnership with the objective to discover and develop first-in-class drugs in the multiple therapeutic areas including cancer, rheumatoid arthritis and liver related diseases.

Jinhan Kim, Standigm CEO, spoke about StandigmAI, the drug repositioning solution, in the Precision Medicine World Conference (PMWC) Silicon Valley.

Standigm, Inc. today announced that it has raised $3 million (3.4 billion won) in seed funding from three capital firms: K-Cube Ventures LLC, LB Investment, Inc., and Autism Investment Co., Ltd.

Standigm had participated in the AstraZeneca-Sanger Drug Combination Prediction Dream Challenge hosted by one of the leading pharmaceutical companies, AstraZeneca. Standigm team ranked third among 71 international teams. Standigm will apply the methods to precision medicine, patient stratification, and therapeutic/diagnostic design.

K Cube Ventures and BonAngels also made the initial investments in Vuno, Solidware, UVify and Standigm as well as Lunit.